Format

Send to

Choose Destination
See comment in PubMed Commons below
Leukemia. 2009 Aug;23(8):1374-7. doi: 10.1038/leu.2009.75. Epub 2009 Apr 9.

NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia.

Author information

1
Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA.

Abstract

Inhibition of NOTCH1 signaling with gamma-secretase inhibitors (GSIs) has been proposed as a molecularly targeted therapy in T-cell acute lymphoblastic leukemia (T-ALL). However, GSIs seem to have limited antileukemic activity in human T-ALL and are associated with severe gastrointestinal toxicity resulting from inhibition of NOTCH signaling in the gut. Inhibition of NOTCH1 signaling in glucocorticoid-resistant T-ALL restored glucocorticoid sensitivity and co-treatment with glucocorticoids inhibited GSI-induced gut toxicity. Thus, combination therapies with GSIs plus glucocorticoids may offer a new opportunity for the use of anti-NOTCH1 therapies in human T-ALL.

PMID:
19357700
PMCID:
PMC2814171
DOI:
10.1038/leu.2009.75
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center